Login
← Go Back
Bafna Pharmaceuticals
BAFNAPH · Pharma > Pharmaceuticals & Drugs · Chairman: Shanmugam Hemalatha Listing date: Nov. 13, 2012
Stock Price vs Company Growth
1d
4.2%
1w
1.8%
1m
13.0%
3m
30.2%
6m
2.6%
1y
30.4%
5y
3.1%
10y
11.8%
all
6.3%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 104 4.2%
104
178
Company Overview
Sales
147 Cr
Growth: -2.3%
Profit after Tax
9.67 Cr
Growth: 10.1%
Micro Cap
247 Cr
P/E: 25.6x
Industry P/E: 27.8x
Fundamentals
Sales (Cr) ₹ 147
Growth -2.3%
EBITDA 10.5%
P/S 1.7x
Dividend 0.0%
P/E 25.6x
Book Value ₹ 39.4
PEG Ratio -11.5x
ROE 10.8%
P/B 2.8x
Shareholding Pattern
Institutions
Promoters
Srjr Lifesciences Llp
90.0 %
Paras Bafna
0.21 %
Navin Bafna M
0.17 %
Amribai Bafna
0.01 %
Others
Monarch Networth Finserve Private Limited
1.4 %
Increase    Decrease    No change
Company Profile Detailed
:The company is engaged in the manufacturing of pharmaceutical products. It exports its products to the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries.Product Range:Anti-DiabeticCardiovascularAnti-HypertensiveBi-Layer AntihypertensiveAwards, accreditations and recognition1995: The company was awarded the WHO GMP.2005: The company bagged the ‘Best Supplier Award’ from the State Pharmaceutical Corporation of Sri Lanka.
Investors (54)
mahaveer...
paras.ba...
monarch....